The US Food and Drug Administration (FDA) has granted marketing authorization to CT-132 (Click Therapeutics), an adjunctive, first-in-class prescription digital therapeutic for the preventive treatment of episodic migraine in adults, its development company announced in a statement. The mobile smartphone app uses biological, psychologic, and behavioral approaches to target pain processing and includes such tools …
Leave a Comment Leave a Comment
